Download PDF
Semin Liver Dis 2014; 34(03): 341-351
DOI: 10.1055/s-0034-1383733
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Old and Novel Therapies for Primary Biliary Cirrhosis

Albert Parés
1   Department of Medicine, University of Barcelona, Liver Unit, Hospital Clínic, IDIBAPS,CIBERehd, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2014 (online)

    Permissions and Reprints

Abstract

Despite the presumed immunological pathogenesis of primary biliary cirrhosis, no clear or even harmful consequences resulted from some specific treatments addressed to modify the immunological condition. However, ursodeoxycholic acid (UDCA; 13–16 mg/kg/d) has clear favorable effects not only by improving biochemical cholestasis, but also by delaying the histological progression. Long -term treatment with UDCA is associated with excellent survival, free of transplantation in cases showing biochemical response at one year. In the remaining patients, data on the effect of fibrates, budesonide, or obeticholic acid are encouraging. Pruritus is usually managed using resins; further steps are needed in resistant cases with the use of rifampicin, naltrexone, sertraline, or invasive procedures such as albumin dialysis. Osteoporosis, which is highly prevalent in patients with deep and prolonged cholestasis, improves with bisphosphonates; current data indicate that both weekly alendronate and monthly ibandronate increase bone mass in patients with osteoporosis. Nutritional and fat-vitamin supplementation is also mandatory in patients with severe cholestasis.

Keywords

ursodeoxycholic acid - fibrates - budesonide - obeticholic acid - bisphosphonates - pruritus - osteoporosis
 

  • References

  • 1 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2) 237-267
    CrossrefPubMedGoogle Scholar
  • 2 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50 (1) 291-308
    CrossrefPubMedGoogle Scholar
  • 3 Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3 (6) 318-328
    CrossrefPubMedGoogle Scholar
  • 4 Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl. 01) S3-S12
    CrossrefPubMedGoogle Scholar
  • 5 Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1987; 1 (8537) 834-836
    PubMedGoogle Scholar
  • 6 Poupon RE, Balkau B, Eschwège E, Poupon R. UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324 (22) 1548-1554
    CrossrefPubMedGoogle Scholar
  • 7 Heathcote EJ, Cauch-Dudek K, Walker V , et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19 (5) 1149-1156
    CrossrefPubMedGoogle Scholar
  • 8 Lindor KD, Dickson ER, Baldus WP , et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106 (5) 1284-1290
    CrossrefPubMedGoogle Scholar
  • 9 Combes B, Carithers Jr RL, Maddrey WC , et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22 (3) 759-766
    CrossrefPubMedGoogle Scholar
  • 10 Parés A, Caballería L, Rodés J , et al; UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000; 32 (4) 561-566
    CrossrefPubMedGoogle Scholar
  • 11 Poupon RE, Lindor KD, Parés A, Chazouillères O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39 (1) 12-16
    CrossrefPubMedGoogle Scholar
  • 12 Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113 (3) 884-890
    CrossrefPubMedGoogle Scholar
  • 13 Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354 (9184) 1053-1060
    CrossrefPubMedGoogle Scholar
  • 14 Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102 (8) 1799-1807
    CrossrefPubMedGoogle Scholar
  • 15 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: CD000551 DOI: 10.1002/14651858.CD000551.
    PubMedGoogle Scholar
  • 16 Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101 (7) 1529-1538
    CrossrefPubMedGoogle Scholar
  • 17 Angulo P, Dickson ER, Therneau TM , et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30 (5) 830-835
    CrossrefPubMedGoogle Scholar
  • 18 Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130 (3) 715-720
    CrossrefPubMedGoogle Scholar
  • 19 Corpechot C, Abenavoli L, Rabahi N , et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48 (3) 871-877
    CrossrefPubMedGoogle Scholar
  • 20 Kuiper EM, Hansen BE, de Vries RA , et al; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136 (4) 1281-1287
    CrossrefPubMedGoogle Scholar
  • 21 Kumagi T, Guindi M, Fischer SE , et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105 (10) 2186-2194
    CrossrefPubMedGoogle Scholar
  • 22 Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55 (6) 1361-1367
    CrossrefPubMedGoogle Scholar
  • 23 Zhang LN, Shi TY, Shi XH , et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013; 58 (1) 264-272
    CrossrefPubMedGoogle Scholar
  • 24 Cavazza A, Caballería L, Floreani A , et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50 (4) 1162-1168
    CrossrefPubMedGoogle Scholar
  • 25 Kuiper EM, Hansen BE, Adang RP , et al; Dutch PBC Study Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2010; 22 (12) 1495-1502
    PubMedGoogle Scholar
  • 26 Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007; 46 (4) 1131-1137
    CrossrefPubMedGoogle Scholar
  • 27 Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95 (1) 326-327
    CrossrefPubMedGoogle Scholar
  • 28 Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95 (10) 2990-2992
    CrossrefPubMedGoogle Scholar
  • 29 Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97 (8) 2147-2149
    CrossrefPubMedGoogle Scholar
  • 30 Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients?. J Gastroenterol 2003; 38 (6) 573-578
    PubMedGoogle Scholar
  • 31 Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol 2005; 40 (2) 157-163
    CrossrefPubMedGoogle Scholar
  • 32 Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006; 41 (7) 686-692
    CrossrefPubMedGoogle Scholar
  • 33 Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009; 49 (1) 337-338 , author reply 338
    CrossrefPubMedGoogle Scholar
  • 34 Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010; 44 (5) 371-373
    PubMedGoogle Scholar
  • 35 Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010; 4: 120-126
    CrossrefPubMedGoogle Scholar
  • 36 Levy C, Peter JA, Nelson DR , et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011; 33 (2) 235-242
    CrossrefPubMedGoogle Scholar
  • 37 Lens S, Leoz M, Nazal L, Bruguera M, Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014; 34 (2) 197-203
    CrossrefPubMedGoogle Scholar
  • 38 Honda A, Ikegami T, Nakamuta M , et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57 (5) 1931-1941
    CrossrefPubMedGoogle Scholar
  • 39 Matsumoto T, Miyazaki H, Nakahashi Y , et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004; 30 (3) 125-136
    CrossrefPubMedGoogle Scholar
  • 40 Chianale J, Vollrath V, Wielandt AM , et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996; 314 (Pt 3) 781-786
    PubMedGoogle Scholar
  • 41 Leuschner M, Maier KP, Schlichting J , et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117 (4) 918-925
    CrossrefPubMedGoogle Scholar
  • 42 Rautiainen H, Kärkkäinen P, Karvonen AL , et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41 (4) 747-752
    CrossrefPubMedGoogle Scholar
  • 43 Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31 (2) 318-323
    CrossrefPubMedGoogle Scholar
  • 44 Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38 (1) 196-202
    PubMedGoogle Scholar
  • 45 Pellicciari R, Fiorucci S, Camaioni E , et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45 (17) 3569-3572
    CrossrefPubMedGoogle Scholar
  • 46 Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13 (7) 298-309
    CrossrefPubMedGoogle Scholar
  • 47 Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 2005; 48 (17) 5383-5403
    CrossrefPubMedGoogle Scholar
  • 48 Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140 (4) 1120-1125 , e1–e12
    CrossrefPubMedGoogle Scholar
  • 49 Fiorucci S, Antonelli E, Rizzo G , et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127 (5) 1497-1512
    CrossrefPubMedGoogle Scholar
  • 50 Fiorucci S, Rizzo G, Antonelli E , et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005; 315 (1) 58-68
    CrossrefPubMedGoogle Scholar
  • 51 Mason A, Luketic VA, Lindor KD , et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (int-747) to ursodeoxycholic acid (Abstract). Hepatology 2010; 52: 375A
    PubMedGoogle Scholar
  • 52 Marschall HU, Luketic V, Lövgren-Sandblom A , et al. The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) increases plasma FGF- 19 concen- trations and decreases bile acid synthesis in primary biliary cirrhosis (PBC) (Abstract). J Hepatol 2012; 56 (Suppl 2): S377
    PubMedGoogle Scholar
  • 53 Kowdley KV, Jones D, Luketic V , et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC (Abstract). J Hepatol 2011; 54: S13
    PubMedGoogle Scholar
  • 54 Myers RP, Swain MG, Lee SS, Shaheen AAM, Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013; 108 (6) 933-941
    CrossrefPubMedGoogle Scholar
  • 55 Hirschfield GM, Liu X, Xu C , et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360 (24) 2544-2555
    CrossrefPubMedGoogle Scholar
  • 56 Xu L, Shen Z, Guo L , et al. Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proc Natl Acad Sci U S A 2003; 100 (14) 8454-8459
    CrossrefPubMedGoogle Scholar
  • 57 Mason AL, Farr GH, Xu L, Hubscher SG, Neuberger JM. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99 (12) 2348-2355
    CrossrefPubMedGoogle Scholar
  • 58 Mason AL, Lindor KD, Bacon BR , et al. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28 (7) 886-894
    CrossrefPubMedGoogle Scholar
  • 59 Hendrickse MT, Rigney E, Giaffer MH , et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117 (2) 400-407
    CrossrefPubMedGoogle Scholar
  • 60 González-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997; 27 (1) 143-149
    CrossrefPubMedGoogle Scholar
  • 61 Combes B, Emerson SS, Flye NL , et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42 (5) 1184-1193
    CrossrefPubMedGoogle Scholar
  • 62 Kaplan MM, Bonder A, Ruthazer R, Bonis PA. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010; 55 (11) 3207-3217
    CrossrefPubMedGoogle Scholar
  • 63 Giljaca V, Poropat G, Stimac D, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010; (5) CD004385
    PubMedGoogle Scholar
  • 64 Bodenheimer Jr H, Schaffner F, Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 95 (1) 124-129
    PubMedGoogle Scholar
  • 65 Kaplan MM, Alling DW, Zimmerman HJ , et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315 (23) 1448-1454
    CrossrefPubMedGoogle Scholar
  • 66 Vuoristo M, Färkkilä M, Karvonen AL , et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995; 108 (5) 1470-1478
    CrossrefPubMedGoogle Scholar
  • 67 Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol 1987; 5 (1) 1-7
    CrossrefPubMedGoogle Scholar
  • 68 Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991; 14 (6) 990-993
    CrossrefPubMedGoogle Scholar
  • 69 Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. UDCA-PBC Study Group. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996; 24 (5) 1098-1103
    CrossrefPubMedGoogle Scholar
  • 70 Gong Y, Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol 2005; 100 (8) 1876-1885
    CrossrefPubMedGoogle Scholar
  • 71 Wiesner RH, Ludwig J, Lindor KD , et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322 (20) 1419-1424
    CrossrefPubMedGoogle Scholar
  • 72 Lombard M, Portmann B, Neuberger J , et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104 (2) 519-526
    PubMedGoogle Scholar
  • 73 Guañabens N, Parés A, Navasa M , et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol 1994; 21 (1) 24-28
    CrossrefPubMedGoogle Scholar
  • 74 Hoofnagle JH, Davis GL, Schafer DF , et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91 (6) 1327-1334
    PubMedGoogle Scholar
  • 75 Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32 (5) 897-900
    CrossrefPubMedGoogle Scholar
  • 76 The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol 1993; 17 (2) 227-235
    CrossrefPubMedGoogle Scholar
  • 77 McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol 1994; 21 (4) 496-499
    CrossrefPubMedGoogle Scholar
  • 78 Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11 (10) 1165-1169
    PubMedGoogle Scholar
  • 79 Leuschner M, Holtmeier J, Ackermann H, Leuschner U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol 2002; 14 (12) 1369-1376
    CrossrefPubMedGoogle Scholar
  • 80 Stojakovic T, Putz-Bankuti C, Fauler G , et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46 (3) 776-784
    CrossrefPubMedGoogle Scholar
  • 81 Cash WJ, O'Neill S, O'Donnell ME , et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013; 33 (8) 1166-1174
    CrossrefPubMedGoogle Scholar
  • 82 Invernizzi P, Alvaro D, Crosignani A, Gaudio E, Podda M. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 2004; 39 (4) 1175-1176
    CrossrefPubMedGoogle Scholar
  • 83 Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96 (9) 2745-2750
    CrossrefPubMedGoogle Scholar
  • 84 Pares A, Caballeria L, Deulofeu R, Rodés J. Circulating fat-soluble vitamins and antioxidants in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2005; 42 (4) 470A
    PubMedGoogle Scholar
  • 85 Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988; 95 (3) 787-792
    PubMedGoogle Scholar
  • 86 Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83 (1 Pt 1) 97-102
    PubMedGoogle Scholar
  • 87 Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology 1989; 96 (2 Pt 1) 479-486
    PubMedGoogle Scholar
  • 88 Carey Jr JB, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA 1961; 176: 432-435
    CrossrefPubMedGoogle Scholar
  • 89 Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest 1972; 51 (11) 2781-2789
    CrossrefPubMedGoogle Scholar
  • 90 Javitt NB. Timing of cholestyramine doses in cholestatic liver disease. N Engl J Med 1974; 290 (23) 1328-1329
    PubMedGoogle Scholar
  • 91 Rust C, Sauter GH, Oswald M , et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000; 30 (2) 135-139
    CrossrefPubMedGoogle Scholar
  • 92 Kuiper EM, van Erpecum KJ, Beuers U , et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52 (4) 1334-1340
    CrossrefPubMedGoogle Scholar
  • 93 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94 (2) 488-493
    PubMedGoogle Scholar
  • 94 Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1 (8638) 574-576
    PubMedGoogle Scholar
  • 95 Podesta A, Lopez P, Terg R , et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36 (2) 216-220
    CrossrefPubMedGoogle Scholar
  • 96 Bachs L, Parés A, Elena M, Piera C, Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102 (6) 2077-2080
    CrossrefPubMedGoogle Scholar
  • 97 Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50 (3) 436-439
    CrossrefPubMedGoogle Scholar
  • 98 Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102 (7) 1528-1536
    CrossrefPubMedGoogle Scholar
  • 99 Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006; 26 (8) 943-948
    CrossrefPubMedGoogle Scholar
  • 100 Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82 (3) 310-317
    CrossrefPubMedGoogle Scholar
  • 101 Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113 (4) 1264-1269
    CrossrefPubMedGoogle Scholar
  • 102 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37 (6) 717-722
    CrossrefPubMedGoogle Scholar
  • 103 Bergasa NV, Schmitt JM, Talbot TL , et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27 (3) 679-684
    CrossrefPubMedGoogle Scholar
  • 104 Bergasa NV, Talbot TL, Alling DW , et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102 (2) 544-549
    PubMedGoogle Scholar
  • 105 Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (12) 2736-2741
    CrossrefPubMedGoogle Scholar
  • 106 Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45 (3) 666-674
    CrossrefPubMedGoogle Scholar
  • 107 Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104 (1) 244-247
    PubMedGoogle Scholar
  • 108 Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990; 37 (Suppl. 02) 122-125
    PubMedGoogle Scholar
  • 109 Cerio R, Murphy GM, Sladen GE, MacDonald DM. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 1987; 116 (2) 265-267
    CrossrefPubMedGoogle Scholar
  • 110 Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985; 26 (3) 291-294
    CrossrefPubMedGoogle Scholar
  • 111 Quintero E, Puig L, Parés A , et al. Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria. Gastroenterol Hepatol 1986; 9 (7) 329-333
    PubMedGoogle Scholar
  • 112 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008; 22 (5) 505-507
    PubMedGoogle Scholar
  • 113 Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006; 45 (6) 887-891
    CrossrefPubMedGoogle Scholar
  • 114 Macia M, Avilés J, Navarro J, Morales S, García J. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003; 114 (1) 62-64
    CrossrefPubMedGoogle Scholar
  • 115 Doria C, Mandalá L, Smith J , et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9 (4) 437-443
    CrossrefPubMedGoogle Scholar
  • 116 Parés A, Cisneros L, Salmerón JM , et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99 (6) 1105-1110
    CrossrefPubMedGoogle Scholar
  • 117 Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53 (2) 307-312
    CrossrefPubMedGoogle Scholar
  • 118 Kremer AE, van Dijk R, Leckie P , et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56 (4) 1391-1400
    CrossrefPubMedGoogle Scholar
  • 119 Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006; 44 (1) 280-281
    CrossrefPubMedGoogle Scholar
  • 120 Newton JL, Pairman J, Sutcliffe K, Wilton K, Jones DEJ. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2008; 6 (2) 228-233
    CrossrefPubMedGoogle Scholar
  • 121 Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006; 44 (1) 91-98
    CrossrefPubMedGoogle Scholar
  • 122 Kaplan MM, Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med 2005; 143 (7) 546-547
    CrossrefPubMedGoogle Scholar
  • 123 Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009; 54 (10) 2242-2246
    CrossrefPubMedGoogle Scholar
  • 124 Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 25 (4) 471-476
    PubMedGoogle Scholar
  • 125 Parés A, Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008; 12 (2) 407-424
    CrossrefPubMedGoogle Scholar
  • 126 Ruiz-Gaspà S, Guañabens N, Enjuanes A , et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010; 40 (1) 25-34
    CrossrefPubMedGoogle Scholar
  • 127 Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N , et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54 (6) 2104-2113
    CrossrefPubMedGoogle Scholar
  • 128 Dubreuil M, Ruiz-Gaspà S, Guañabens N , et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver Int 2013; 33 (7) 1029-1038
    CrossrefPubMedGoogle Scholar
  • 129 Guañabens N, Cerdá D, Monegal A , et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138 (7) 2348-2356
    CrossrefPubMedGoogle Scholar
  • 130 Guañabens N, Parés A, Monegal A , et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113 (1) 219-224
    CrossrefPubMedGoogle Scholar
  • 131 Guañabens N, Parés A, Ros I , et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (10) 2268-2274
    CrossrefPubMedGoogle Scholar
  • 132 Wolfhagen FHJ, van Buuren HR, den Ouden JW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26 (2) 325-330
    CrossrefPubMedGoogle Scholar
  • 133 Musialik J, Petelenz M, Gonciarz Z. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand J Gastroenterol 2005; 40 (7) 873-874
    PubMedGoogle Scholar
  • 134 Zein CO, Jorgensen RA, Clarke B , et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42 (4) 762-771
    CrossrefPubMedGoogle Scholar
  • 135 Guañabens N, Monegal A, Cerdá D , et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013; 58 (6) 2070-2078
    CrossrefPubMedGoogle Scholar
  • 136 Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc 2002; 77 (10) 1031-1043
    CrossrefPubMedGoogle Scholar
  • 137 Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011; 18 (5) 375-381
    CrossrefPubMedGoogle Scholar
  • 138 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5 (11) 1313-1315
    CrossrefPubMedGoogle Scholar
  • 139 Markus BH, Dickson ER, Grambsch PM , et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320 (26) 1709-1713
    CrossrefPubMedGoogle Scholar
  • 140 Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 1992; 102 (1) 310-313
    PubMedGoogle Scholar
  • 141 Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis 2008; 12 (2) 461-472 , xi
    CrossrefPubMedGoogle Scholar